Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technol…

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), wholly owned subsidiary, Buzz Bomb Caffeine ...

Aspire Biopharma Secures Agreement with Microsize for Development of Novel Sublingual Aspirin

Microsize brings over thirty years of expertise in specialized particle size engineering for the pharmaceutical industry, ...

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam – Generic Xanax(R) – for Rapid Anxiety Relief

New sublingual delivery system designed to enhance bioavailability and speed of onset for major depressive and ...

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Powder Formulation of Clopidogrel (Generic Plavix(R)) to Address Gastric Bleeding Risks

New sublingual delivery system designed to enhance bioavailability and avoid gastric side effects many patients experience with clopidogrel.
The Manila Times

LuminEye Nano-Drops Product Information Updated as Consumer Interest in Eye Health Supplement Options and Vision Support Alternatives Grows in 2026

An informational overview examining category context, publicly available product disclosures, and what consumers often ...

Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity

Strategic inventory of 100,000 20-packs now available to meet increasing demand for rapid-onset sublingual caffeine ...
Multiple Sclerosis News Today

Dissolvable film may deliver more MS medicine than standard tablets

Dissolvable film BNT23001 led to about 40% higher cladribine exposure than tablets in a preclinical pig study, BioNxt ...
Healio

Sublingual epinephrine film moving forward, NDA anticipated by early next year

Please provide your email address to receive an email when new articles are posted on . Aquestive aims to submit a new drug application in the first quarter of 2025. The company hopes to launch in ...

Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit

TONMYA demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT studyUnique sublingual formulation ...
Monthly Prescribing Reference

Sublingual Cyclobenzaprine Reduces Pain in Patients With Fibromyalgia

TNX-102 SL is intended to be taken once at bedtime for the management of fibromyalgia. Treatment with TNX-102 SL (cyclobenzaprine HCl sublingual tablets) significantly reduced daily pain in patients ...